Navigation Links
Biotest Pharmaceuticals Corporation Announces Management Team
Date:12/4/2007

BOCA RATON, Fla., Dec. 4 /PRNewswire/ -- Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, today announced the company's new management team as part of the formal completion of Biotest AG's acquisition of Nabi Pharmaceuticals (Nasdaq: NABI) and the creation of Biotest Pharmaceuticals. Please see the separate press release, "Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit," December 4, 2007 for more information.

"The team that we have assembled to run Biotest Pharmaceuticals represents leaders from both Biotest AG and Nabi Pharmaceuticals. They are proven professionals and bring to our new company extensive expertise in research, development and business management," said Professor Dr. Gregor Schulz, Chairman of the Management Board of Biotest AG. "We are confident that, led by this team, Biotest Pharmaceuticals will become a U.S. leader in the immunology biotherapeutic field."
Biotest Pharmaceuticals will be led by the following management team:

-- Chief Executive Officer - Rainer Pabst, PhD. Dr. Pabst is a biochemist

who previously served as Managing Director of Biotest Pharma GmbH.

Prior to that, he served as Vice President, Technical Operations for

Bayer Corp. Biological Products, Vice President Industrial Operations

at Centeon Pharma GmbH, and Head of Plasma Proteins Production at

Behringwerke AG. In his role as CEO, Dr. Pabst will be responsible for

the executive leadership and the operational execution of Biotest

Pharmaceuticals.

-- Chief Financial Officer - Jordan I. Siegel, CPA, MBA. Mr. Siegel

previously served as Senior Vice President, Finance, Chief Financial

Officer and Treasurer for Nabi Biopharmaceuticals. Prior to joining

Nabi, he served as Vice President of Finance for IVAX Pharmaceuticals,

Inc and previously as IVAX's Vice President and Treasurer. In his role

as CFO, Mr. Siegel will be responsible for the financial management and

reporting of Biotest Pharmaceuticals. To facilitate the transition

period for Nabi Biopharmaceuticals, Mr. Siegel also will continue to

hold the position of CFO at Nabi through March 2008.

-- Vice President of Project Management - Peter Seith. Mr. Seith

previously served as one of the Directors of Project Management for

Biotest Pharma GmbH. Prior to that, he was the Director of Quality

Assurance at CSL Behring. Mr. Seith will serve a dual role responsible

for both project management for Biotest Pharmaceuticals in Boca Raton

and Vice President of Corporate Quality Assurance for Biotest Pharma

worldwide.

"Biotest Pharmaceuticals draws upon the success and experience of two established leaders in the field of immunology and plasma products -- our parent company, Biotest AG, and Nabi Biopharmaceuticals," said Dr. Rainer Pabst, Chief Executive Officer of Biotest Pharmaceuticals. "With the completion of our acquisition of Nabi's Biologics business, pipeline and key assets, we feel we are founding Biotest Pharmaceuticals with a solid foundation, a high quality workforce, state-of-the-art facilities and a promising pipeline of biotherapeutic products. We look forward to realizing our potential and driving the growth of Biotest Pharmaceuticals as we move forward together."

About Biotest Pharmaceuticals Corporation

Biotest Pharmaceuticals Corporation develops and manufactures pharmaceutical and biotherapeutic products with a specialization in immunology. Biotest Pharmaceuticals will offer the hyperimmunoglobulin Nabi- HB(R), a key product used in the prevention of hepatitis B. Biotest Pharmaceuticals also is currently working to develop additional products including a polyvalent immunoglobulin (IVIG, Phase III) and Civacir(R) (Phase IIb), for the prevention of hepatitis C in liver transplant patients. Biotest Pharmaceuticals was formed in 2007 as part of the Biotest AG acquisition of Nabi Pharmaceuticals' Biologics business unit, including its plasmapheresis centers across the United States. The company employs approximately 500 people in the U.S. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German-based global provider of plasma proteins that employs approximately 1,750 people worldwide.

About Biotest AG

Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialized in immunology and haematology. In its Pharmaceutical segment, Biotest develops and markets immunoglobulins, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or hematopoietic system. In the Biotherapeutic segment, Biotest researches in the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and serology and microbiology systems which are predominantly used in hygiene control, as well as serology, used, for example, in blood transfusions. Biotest has around 1,750 employees worldwide and its shares are listed in the Frankfurt Stock Exchange's Prime Standard.


'/>"/>
SOURCE Biotest Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
2. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):